Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment withdrawal · people with epilepsy
VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation · people with epilepsy
It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with epilepsy
VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
Treatment withdrawal · people with epilepsy and depression
Sertraline showed no clear difference in withdrawals compared with cognitive behavioural therapy (moderate certainty).
1 finding from 1 review
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Quality of life (QOLIE‐89) (1‐ to 3‐month periods) · people with epilepsy and depression
1 finding from 1 review
Adverse effects · people with epilepsy and depression
1 finding from 1 review